Ozempic Approved in India: What You Need to Know About the Promising Weight Loss and Diabetes Drug

India has taken a pivotal step in the fight against diabetes and obesity by approving Ozempic (semaglutide), a once-weekly injectable medication, for clinical use in adults with type 2 diabetes. The Central Drugs Standard Control Organisation (CDSCO), India’s leading drug authority, granted this approval in September 2025, marking a significant advance in chronic disease management for the nation often dubbed the world’s diabetes capital.

A New Era in Diabetes and Weight Management

Ozempic, developed by Danish pharmaceutical firm Novo Nordisk, belongs to a class of drugs known as GLP-1 receptor agonists. It mimics the action of glucagon-like peptide-1, a natural hormone that promotes insulin release, curbs glucagon secretion (which otherwise raises blood sugar), and slows stomach emptying, leading to prolonged feelings of fullness.

The medication is administered via a once-weekly injection and is recommended as an adjunct to diet and exercise, primarily for adults living with type 2 diabetes who have struggled to achieve adequate glycemic control with lifestyle measures alone. However, Ozempic’s global profile has soared due to robust evidence of its benefits in supporting clinically meaningful weight loss among adults with obesity or overweight.

Key Findings From Leading Clinical Trials

The arrival of Ozempic in India is underpinned by a compelling body of international research:

• Weight Loss Efficacy: In landmark studies, including the SELECT and STEP 5 trials, adults treated with semaglutide experienced average weight reductions of around 10–15% over two years, significantly outperforming placebo groups—which saw reductions of less than 3%.

  • In the SELECT trial (17,604 participants, 41 countries), individuals who received semaglutide lost an average of 10.2% of their body weight over 4 years.

  • In the STEP 5 trial (304 adults, 104 weeks), the mean weight reduction for those on semaglutide was 15.2%, compared to 2.6% for placebo.

• Metabolic & Cardiovascular Benefits: Beyond weight loss, semaglutide has been associated with major reductions in cardiovascular morbidity. The SELECT study found a 20% reduction in the risk of major adverse cardiovascular events in adults with overweight or obesity (but without diabetes).

• Improvements in Metabolic Health: Trials report reductions in waist circumference, improvements in blood pressure, blood sugar regulation, and cholesterol levels—offering multifaceted metabolic improvements.

Dr. Sanchayan Roy, an internal medicine expert, highlighted the importance of Ozempic’s dual benefits, stating: “Ozempic is well-known for its role in aiding weight loss and enhancing metabolic health, making it a valuable addition for people struggling with both diabetes and obesity”.

How Does Ozempic Work?

Ozempic’s active ingredient, semaglutide, helps:

• Boost insulin release in response to meals.

• Suppress unnecessary sugar output from the liver.

• Slow stomach emptying to reduce appetite and calorie intake.

These combined effects are particularly valuable for people facing challenges related to both high blood sugar and excessive weight, conditions that frequently overlap in India’s growing urban centers.

Real-World Impact and Accessibility in India

India has the second-highest number of people with type 2 diabetes globally, and projections indicate numbers could surpass 100 million by 2045. The approval and upcoming launch of Ozempic could have far-reaching implications for Indian patients, offering a modern, evidence-backed alternative to traditional therapies.

Healthcare leaders, including Vikrant Shrotriya, Managing Director of Novo Nordisk India, have expressed optimism: “We strive to introduce the best-in-class innovations for the people who need it the most.” The approval is also expected to enhance competition, potentially bringing down the long-term costs as generic versions become available in 2026.

Safety Profile: What Are the Risks?

Like all medications, Ozempic is not without potential side effects:

• Common Side Effects: Nausea, vomiting, diarrhea, constipation, and stomach discomfort are the most frequently reported, usually emerging during the first weeks of therapy. In trials, gastrointestinal issues affected up to 82% of participants (compared to 54% on placebo), though most were mild to moderate and temporary.

• Less Common Risks: A minority of users experience gallbladder problems (such as gallstones), kidney function changes, or, rarely, pancreatitis.

• Psychological Concerns: Recent post-marketing surveillance has included reports of mood changes or anxiety, though large safety reviews by U.S. and European regulatory agencies have found no proof that semaglutide causes suicidal thoughts or actions.

• Treatment Discontinuation: Nearly 17% of participants in real-world studies stopped the medication due to side effects.

Dr. Manish Gupta, an independent endocrinologist, cautions: “While semaglutide represents true innovation, it is not suitable for everyone. Careful medical supervision is essential, especially for those with a history of pancreatitis or gallbladder disease.”

Potential Limitations and Counterarguments

Despite the positive data, some limitations exist:

• The largest studies have been conducted abroad, and while Asian patient data is promising, the degree of weight loss was somewhat less pronounced compared to Western populations.

• Cost and accessibility may be a concern for many in India until generic versions enter the market.

• Long-term safety in “off-label” populations (such as non-diabetic people using semaglutide purely for weight loss) requires additional monitoring and research.

Practical Takeaways for Readers

Ozempic’s approval offers hope to millions living with diabetes and obesity in India, but it is not a substitute for foundational health habits. The drug should be used alongside balanced nutrition and regular physical activity, under the guidance of a healthcare professional. It is not recommended for casual or cosmetic weight loss.

Patients considering Ozempic should be prepared for possible temporary side effects and should discuss their complete medical history, including any pancreas or kidney issues, with their doctor.

Medical Disclaimer

“Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.”

References